In a surprising development, Dr. Vinay Prasad has returned to the Food and Drug Administration (FDA) to resume leadership of the Center for Biologics Evaluation and Research (CBER) just weeks after his abrupt resignation. His departure and return were amid mounting tensions related to gene therapy regulatory decisions and political criticism. This revolving door scenario has stirred uncertainty about FDA's internal operations during a critical period overseeing vaccines and gene therapies. Meanwhile, FDA leadership, including George Tidmarsh, is striving to stabilize agency operations and restore normalcy amid these challenges. The agency also faces scrutiny over decision-making processes lacking transparency. These events highlight ongoing tensions at the regulatory agency influencing biopharma innovation and oversight.